Unfortunately, regorafenib has been associated with certain adverse events (AEs), such as hand-foot skin reaction (HFSR) and hypertension.
Regorafenib is an anti-VEGF oral therapy that was approved by the Food and Drug Administration (FDA) in 2012 for use in patients with advanced colorectal cancer previously treated with chemotherapy. In 2013, the FDA approved it for patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumors who have been previously treated with imatinib and sunitinib. Unfortunately, regorafenib has been associated with certain adverse events (AEs), such as hand-foot skin reaction (HFSR) and hypertension.
Paulo Marcelo Hoff, MD, PhD, FACP, on Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRC
Hoff is from the University of São Paulo, Brazil.
In their poster presentation at this year’s Oncology Nursing Society Congress, Robin Wachsman, RN, BSN, CCRN, OCN, BCRN, of West Cancer Center in Memphis, Tennessee, and Cathy Maxwell, RN, OCN, of Advanced Medical Specialties in Miami, Florida, provided an overview of strategies and best practices for the management of these and other AEs, to help ensure patients will adhere to therapy and achieve maximal therapeutic benefit.
Onset of AEs is typically observed in the first treatment cycle, the researchers note, and often eases later on, making it advisable for patients to be seen weekly during the first cycle of therapy. Wachsman and Maxwell stress that providing thorough education before treatment begins is essential in order to counsel patients on what to report and when to report it. They also note that HFSR can be managed successfully with such measures as moisturizers and avoiding trauma or unusual friction to the feet, and that hypertension is controllable with regular monitoring (See box).
The following suggestions may help avoid reactions and relieve them if they do happen:
This information was adapted from Cancer.Net. Skin reactions to targeted therapies.http://www.cancer.net/navigating-cancer-care/side-effects/skin-reactions-targeted-therapies